Royalty Pharma plc (NASDAQ: RPRX) reported Q3 resutls. Revenue for the quarter came in at $573 million versus the consensus estimate of $584.92 million.

GUIDANCE:

Adjusted Cash Receipts expected to be $2,750 to $2,800 million, which includes $458m from the acceleration of payments related to Pfizer’s acquisition of Biohaven.

For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.